Low-dose, subcutaneous recombinant human granulocyte colony-stimulating factor (rHuG-CSF, Lenograstim®) was administered to 40 cancer patients (17 men, 23 women) enrolled from two medical centers to verify its clinical effectiveness and safety. The patient's mean age was 50.3 ± 14.9 years. In this study, there were 20 patients with non-Hodgkin's lymphoma, 10 with breast cancer and 10 with various other solid tumors. The patients first received a course of chemotherapy without rHuG-CSF (control cycle). All patients had at least one episode of neutropenia or leukopenia during the control cycle. rHuG-CSF (2 μg/kg/day) was given subcutaneously for 10 days during the study cycle starting on the fourth day of chemotherapy. The nadirs of absolute neutrophil counts (ANC) were 1.8 ± 0.25 x 109/L and 0.27 ± 0.05 x 109/L for the rHuG-CSF cycle and pre-rHuG-CSF control cycle, respectively. The number of days of ANC <1 x 109/L were 1.03 ± 0.29 and 7.38 ± 0.58 for rHuG-CSF and control cycles, respectively. The duration from nadir to recovery of ANC (≤ 2 x 109/L) was 9.68 ± 1.15 days in the rHuG-CSF cycle, vs 22.53 ± 1.03 days in control cycle (p <0.0001). No patient withdrew from the study. Adverse events were mild, with 12.5% to 40% of patients developing myalgia, general malaise, back pain, anorexia or fever. These side-effects were tolerable in all cases. The biochemical abnormalities were subtle and negligible. rHuG-CSF 2μg/kg/day given subcutaneously for 10 days beginning on the fourth day of chemotherapy is very effective (90%), safe and convenient.
|頁（從 - 到）||845-850|
|期刊||Journal of the Formosan Medical Association = Taiwan yi zhi|
|出版狀態||已發佈 - 十一月 1996|
ASJC Scopus subject areas